Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide first add-on treatment in focal epilepsy
ChiCTR2100047311Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zonisamide in Focal Onset Epilepsy and focal to bilateral tonic-clonic seizure, sponsored by Qilu Hospital of Shandong University. Primary endpoints: Change in seizure frequency per 4 weeks and 50% responder rate. Started May 2021; status: recruiting.
02
Drugs
zonisamide
03
Conditions
Focal Onset Epilepsyfocal to bilateral tonic-clonic seizure
Beyond the preview
Go deeper on ChiCTR2100047311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047311.